Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Is everyone ready for "personalized medicine"...not...but it's moving fast and will change the way medicine is practiced....it will be in the genes...next issue to to get the real time clinical information available to every MD in a timely manner, the genes will be doing much of the selection process in the future to determine which drug (if there is choice of more than one) which will better match the comparison with the patient genes...there are over 1000 lab tests already in the biotech area and it's growing fast. BD

Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, has announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million.

The grant, entitled "DNA Diagnostic System for Statin Safety and Efficacy," was awarded by the National Institute of General Medical Sciences (NIGMS).
Statins are the most prescribed drugs in the world. Drugs in this class include atorvastatin (Lipitor(R)), rosuvastatin (Crestor(R)), and simvastatin (Zocor(R) and generic formulations). Statin-induced neuro-myopathy (SINM) is the main clinically relevant safety risk of these drugs. In medical practice, SINM presents as a constellation of nerve and muscle side effects. Clinical symptoms of SINM include muscle aches (myalgia), cramps, weakness, and muscle injury (myositis, monitored in serum by elevation of certain enzymes). Statin usage is ultimately limited by these side effects which are disabling to 10% of patients, require alteration of therapy, burden healthcare with management costs, and reduce compliance.